NASDAQ:GTXI

GTX (GTXI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$8.45
$9.08
50-Day Range
$1.20
$7.20
52-Week Range
$0.74
$25.60
Volume
1,657 shs
Average Volume
390,540 shs
Market Capitalization
$205.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GTXI stock logo

About GTX Stock (NASDAQ:GTXI)

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

GTXI Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Volkswagen reveals hot new ID Buzz GTX
See More Headlines
Receive GTXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GTX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2018
Today
4/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GTXI
CUSIP
40052B10
Fax
N/A
Employees
21
Year Founded
N/A

Profitability

Net Income
$-38,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.09 per share

Miscellaneous

Free Float
N/A
Market Cap
$205.63 million
Optionable
Not Optionable
Beta
2.22
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Robert James Wills B.S. (Age 65)
    M.S., Ph.D., Exec. Chairman
  • Mr. Marc S. Hanover (Age 56)
    Co-Founder, CEO & Director
  • Mr. Henry P. Doggrell (Age 70)
    VP, Chief Legal Officer & Sec.
  • Mr. Jason T. Shackelford (Age 44)
    VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller
  • Dr. Diane C. Young (Age 62)
    VP & Chief Medical Officer

GTXI Stock Analysis - Frequently Asked Questions

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) released its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09.

What other stocks do shareholders of GTX own?
This page (NASDAQ:GTXI) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners